Top-Rated StocksTop-RatedNASDAQ:ITCI Intra-Cellular Therapies (ITCI) Stock Price, News & Analysis → The ONE AI Stock to own now. (It’s not Nvidia.) (From Weiss Ratings) (Ad) Free ITCI Stock Alerts $67.77 -0.64 (-0.94%) (As of 06/14/2024 ET) Add Compare Share Share Today's Range$66.57▼$69.2850-Day Range$64.76▼$79.8452-Week Range$45.50▼$84.89Volume636,038 shsAverage Volume673,174 shsMarket Capitalization$7.15 billionP/E RatioN/ADividend YieldN/APrice Target$91.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Intra-Cellular Therapies alerts: Email Address Intra-Cellular Therapies MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.91 Rating ScoreUpside/Downside35.0% Upside$91.50 Price TargetShort InterestHealthy3.79% of Shares Sold ShortDividend StrengthN/ASustainability-1.23Upright™ Environmental ScoreNews Sentiment1.07Based on 11 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.51) to $0.93 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.67 out of 5 starsMedical Sector58th out of 914 stocksPharmaceutical Preparations Industry22nd out of 429 stocks 4.5 Analyst's Opinion Consensus RatingIntra-Cellular Therapies has received a consensus rating of Moderate Buy. The company's average rating score is 2.91, and is based on 10 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageIntra-Cellular Therapies has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Intra-Cellular Therapies' stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted3.79% of the outstanding shares of Intra-Cellular Therapies have been sold short.Short Interest Ratio / Days to CoverIntra-Cellular Therapies has a short interest ratio ("days to cover") of 4.3.Change versus previous monthShort interest in Intra-Cellular Therapies has recently decreased by 12.09%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldIntra-Cellular Therapies does not currently pay a dividend.Dividend GrowthIntra-Cellular Therapies does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreIntra-Cellular Therapies has received a 69.69% net impact score from Upright. The largest positive contribution comes from its "Mental diseases" impact, which is mostly driven by its "Antipsychotics", "Clinical research services for mood disorders", and "Clinical research services for substance abuse disorders " products. See details.Environmental SustainabilityThe Environmental Impact score for Intra-Cellular Therapies is -1.23. Previous Next 2.8 News and Social Media Coverage News SentimentIntra-Cellular Therapies has a news sentiment score of 1.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.91 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Intra-Cellular Therapies this week, compared to 5 articles on an average week.Search InterestOnly 1 people have searched for ITCI on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Intra-Cellular Therapies to their MarketBeat watchlist in the last 30 days. This is a decrease of -98% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Intra-Cellular Therapies insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.40% of the stock of Intra-Cellular Therapies is held by insiders.Percentage Held by Institutions92.33% of the stock of Intra-Cellular Therapies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Intra-Cellular Therapies' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Intra-Cellular Therapies are expected to grow in the coming year, from ($0.51) to $0.93 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Intra-Cellular Therapies is -58.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Intra-Cellular Therapies is -58.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIntra-Cellular Therapies has a P/B Ratio of 11.02. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Intra-Cellular Therapies' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsThe ONE AI Stock to own now. (It’s not Nvidia.)Don’t panic — you haven’t missed the boat on AI. In fact, it has barely launched. Sure, the early stages of this boom were big … But I believe the real wealth in AI has yet to be made …Click here to see the presentation now. About Intra-Cellular Therapies Stock (NASDAQ:ITCI)Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.Read More ITCI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ITCI Stock News HeadlinesJune 14 at 11:48 AM | americanbankingnews.comCantor Fitzgerald Reiterates "Overweight" Rating for Intra-Cellular Therapies (NASDAQ:ITCI)June 12, 2024 | americanbankingnews.comJPMorgan Chase & Co. Raises Intra-Cellular Therapies (NASDAQ:ITCI) Price Target to $78.00June 10, 2024 | globenewswire.comIntra-Cellular Therapies to Present at the 45th Annual Goldman Sachs Global Healthcare ConferenceMay 30, 2024 | investorplace.comThe Secret Stock Stash: 3 Overlooked Picks That Belong in Every PortfolioMay 29, 2024 | ca.finance.yahoo.comITCI Aug 2024 65.000 putMay 29, 2024 | globenewswire.comIntra-Cellular Therapies to Present at the Jefferies Global Healthcare ConferenceMay 23, 2024 | globenewswire.comIntra-Cellular Therapies Highlights Data Presentations at the American Society of Clinical Psychopharmacology Annual MeetingMay 10, 2024 | markets.businessinsider.comMaintained Buy Rating on ITCI Shares Amidst Strong Caplyta Revenue and Positive MDD Study OutlookMay 8, 2024 | finance.yahoo.comIntra-Cellular Therapies, Inc. (NASDAQ:ITCI) Q1 2024 Earnings Call TranscriptMay 8, 2024 | finance.yahoo.comIntra-Cellular Therapies Inc (ITCI) Q1 2024 Earnings Call Transcript Highlights: Robust Revenue ...May 7, 2024 | finanznachrichten.deIntra-Cellular Therapies Inc.: Intra-Cellular Therapies Reports First Quarter 2024 Financial ResultsMay 7, 2024 | markets.businessinsider.comBuy Rating Affirmed: Intra-Cellular Therapies Exceeds Q1 Expectations with Caplyta Sales SurgeMay 7, 2024 | msn.comITCI Stock Earnings: Intra-Cellular Therapies Beats EPS, Beats Revenue for Q1 2024May 7, 2024 | finance.yahoo.comIntra-Cellular Therapies Surpasses Q1 Revenue Estimates with Strong CAPLYTA SalesMay 7, 2024 | msn.comIntra-Cellular Therapies beats Q1 estimatesMay 7, 2024 | globenewswire.comIntra-Cellular Therapies Reports First Quarter 2024 Financial ResultsApril 30, 2024 | globenewswire.comIntra-Cellular Therapies to Host First Quarter 2024 Financial Results Conference Call and WebcastApril 24, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: BioLife Solutions (BLFS) and Intra-Cellular Therapies (ITCI)April 24, 2024 | finance.yahoo.comIntra-Cellular Therapies Announces Closing of $575 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional SharesApril 24, 2024 | globenewswire.comIntra-Cellular Therapies Announces Closing of $575 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional SharesApril 24, 2024 | investorplace.com3 Biotech Stocks With Skyrocketing Potential: April 2024April 22, 2024 | msn.comIpsen, Skyhawk enter RNA targeting research collab in rare neurological diseasesApril 20, 2024 | money.usnews.comIntra-Cellular Therapies IncApril 17, 2024 | globenewswire.comIntra-Cellular Therapies Prices Public Offering of Common StockApril 17, 2024 | investors.comBiotech Leader Intra-Cellular Soars 23%, Breaks Out Past Latest Buy PointSee More Headlines Receive ITCI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Intra-Cellular Therapies and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/07/2024Today6/16/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ITCI CUSIPN/A CIK1567514 Webwww.intracellulartherapies.com Phone(464) 440-9333Fax646-440-9334Employees610Year FoundedN/APrice Target and Rating Average Stock Price Target$91.50 High Stock Price Target$120.00 Low Stock Price Target$77.00 Potential Upside/Downside+35.0%Consensus RatingModerate Buy Rating Score (0-4)2.91 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)($1.16) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-139,670,000.00 Net Margins-21.57% Pretax Margin-21.38% Return on Equity-18.49% Return on Assets-15.26% Debt Debt-to-Equity RatioN/A Current Ratio5.12 Quick Ratio5.00 Sales & Book Value Annual Sales$512.29 million Price / Sales13.97 Cash FlowN/A Price / Cash FlowN/A Book Value$6.15 per share Price / Book11.02Miscellaneous Outstanding Shares105,575,000Free Float101,985,000Market Cap$7.15 billion OptionableOptionable Beta0.97 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Sharon Mates Ph.D. (Age 71)Co-Founder, Chairman & CEO Comp: $2.23MMr. Michael I. Halstead J.D. (Age 51)President Comp: $983.65kDr. Suresh K. Durgam M.D. (Age 55)Executive VP & Chief Medical Officer Comp: $961.84kMr. Mark Neumann (Age 61)EVP & Chief Commercial Officer Comp: $998.36kDr. Robert E. Davis Ph.D. (Age 73)Senior VP & Chief Scientific Officer Comp: $646.12kMr. Juan Fernando Sanchez (Age 53)Vice President of Corporate Communications & Investor Relations Comp: $296.75kMs. Karen Patruno Sheehy Esq. (Age 62)Senior VP & Chief Compliance Officer Dr. Michael OlchaskeySenior VP & Head of Regulatory AffairsMr. John A. BardiSenior VP of Market Access, Policy & Government AffairsDr. Willie R. Earley M.D.Senior VP & Head of Clinical DevelopmentMore ExecutivesKey CompetitorsViela BioNASDAQ:VIERa PharmaceuticalsNASDAQ:RARXAimmune TherapeuticsNASDAQ:AIMTKura OncologyNASDAQ:KURAIronwood PharmaceuticalsNASDAQ:IRWDView All CompetitorsInsiders & InstitutionsTeachers Retirement System of The State of KentuckySold 660 shares on 5/28/2024Ownership: 0.010%Farallon Capital Management LLCBought 231,000 shares on 5/24/2024Ownership: 0.219%Castleark Management LLCSold 19,570 shares on 5/17/2024Ownership: 0.051%Walleye Trading LLCBought 26,200 shares on 5/17/2024Ownership: 0.000%Tidal Investments LLCBought 450 shares on 5/17/2024Ownership: 0.004%View All Insider TransactionsView All Institutional Transactions ITCI Stock Analysis - Frequently Asked Questions Should I buy or sell Intra-Cellular Therapies stock right now? 11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intra-Cellular Therapies in the last year. There are currently 1 hold rating and 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ITCI shares. View ITCI analyst ratings or view top-rated stocks. What is Intra-Cellular Therapies' stock price target for 2024? 11 brokers have issued 12 month price targets for Intra-Cellular Therapies' stock. Their ITCI share price targets range from $77.00 to $120.00. On average, they anticipate the company's share price to reach $91.50 in the next year. This suggests a possible upside of 35.0% from the stock's current price. View analysts price targets for ITCI or view top-rated stocks among Wall Street analysts. How have ITCI shares performed in 2024? Intra-Cellular Therapies' stock was trading at $71.62 at the beginning of 2024. Since then, ITCI shares have decreased by 5.4% and is now trading at $67.77. View the best growth stocks for 2024 here. Are investors shorting Intra-Cellular Therapies? Intra-Cellular Therapies saw a drop in short interest in May. As of May 31st, there was short interest totaling 4,000,000 shares, a drop of 12.1% from the May 15th total of 4,550,000 shares. Based on an average trading volume of 928,400 shares, the days-to-cover ratio is presently 4.3 days. View Intra-Cellular Therapies' Short Interest. When is Intra-Cellular Therapies' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024. View our ITCI earnings forecast. How were Intra-Cellular Therapies' earnings last quarter? Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) issued its quarterly earnings results on Tuesday, May, 7th. The biopharmaceutical company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.31) by $0.15. The biopharmaceutical company had revenue of $144.90 million for the quarter, compared to analyst estimates of $141.41 million. Intra-Cellular Therapies had a negative trailing twelve-month return on equity of 18.49% and a negative net margin of 21.57%. The firm's quarterly revenue was up 52.0% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.46) earnings per share. What ETFs hold Intra-Cellular Therapies' stock? ETFs with the largest weight of Intra-Cellular Therapies (NASDAQ:ITCI) stock in their portfolio include AdvisorShares Psychedelics ETF (PSIL), SPDR S&P Pharmaceuticals ETF (XPH), iShares Neuroscience and Healthcare ETF (IBRN), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), First Trust NYSE Arca Biotechnology Index Fund (FBT), Invesco Biotechnology & Genome ETF (PBE), iShares U.S. Pharmaceuticals ETF (IHE) and Virtus LifeSci Biotech Products ETF (BBP). What other stocks do shareholders of Intra-Cellular Therapies own? Based on aggregate information from My MarketBeat watchlists, some companies that other Intra-Cellular Therapies investors own include Sorrento Therapeutics (SRNE), Amarin (AMRN), Gilead Sciences (GILD), CRISPR Therapeutics (CRSP), Synergy Pharmaceuticals (SGYP), Myovant Sciences (MYOV), Novavax (NVAX), Pfizer (PFE), AbbVie (ABBV) and Clovis Oncology (CLVS). Who are Intra-Cellular Therapies' major shareholders? Intra-Cellular Therapies' stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (9.53%), Wasatch Advisors LP (3.98%), Bellevue Group AG (2.67%), Avoro Capital Advisors LLC (2.34%), Clearbridge Investments LLC (1.65%) and Price T Rowe Associates Inc. MD (1.14%). Insiders that own company stock include Joel S Marcus, Lawrence J Hineline, Lawrence J Hineline, Mark Neumann, Michael Halstead, Nostrand Robert L Van, Rory B Riggs, Sharon Mates, Suresh K Durgam and Suresh K Durgam. View institutional ownership trends. How do I buy shares of Intra-Cellular Therapies? Shares of ITCI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ITCI) was last updated on 6/16/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredHow Biden has already won 2024Obama’s Forever Term [Exposed] or Obama Biden has already won 2024 Exposed: the shocking election plot that...Porter & Company | SponsoredBiden Nomination CANCELED?And I believe when they do take the oath of office, their fingers will be crossed… and America will descend in...The Freeport Society | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Intra-Cellular Therapies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Intra-Cellular Therapies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.